|
Corporate Social Responsibility
News
9.06.2005 ET
|
CSR News from:
|
|
|
News Category:
|
|
Katrina Diabetes Patients Receive First Shipments Of Bayer Blood Glucose Testing Equipment
Meets Urgent Needs Of Gulf Coast Region's High Diabetes Incidence Rate
(CSRwire) PITTSBURGH - In response to urgent requests for diabetes testing
equipment for Hurricane Katrina victims, Bayer is providing more than
45,000 Ascensia® BRIO® blood glucose monitors and enough Ascensia®
EASYFILL® test strips for 45,000 people with diabetes to test for
approximately one month at the recommended American Diabetes Association
guideline level.
The first 1,000 blood glucose monitors and test strips were shipped, at
the request of a local American Red Cross Chapter, to help in the
treatment of hurricane victims with diabetes who have sought refuge in the
Houston region, including Baytown, Texas. Bayer management and employees
are part of the around-the-clock local effort in Baytown, including
cooking meals at the Bayer MaterialScience facility there and delivering
them to the local shelters.
According to the Centers for Disease Control, residents of the areas most
affected by Hurricane Katrina have diabetes rates higher than the U.S.
national average. If left untreated, high blood sugar levels can lead to
kidney failure, heart disease and stroke.
The pledge by Bayer nearly doubled the company's initial commitment of $2
million in cash and product donations. Bayer officials are working
closely with American Red Cross representatives to identify products of
need from its health care, crop science and material sciences
businesses.
Additionally, last Wednesday, Bayer Corporation announced that, together
with the Bayer Foundation, it will match Bayer employee donations dollar
for dollar, which will also be donated to the American Red Cross.
"The images and reports of the suffering and distress in the United States
have touched us deeply," said Bayer AG Management Board Chairman Werner
Wenning. "As a global company, we feel for everyone who has been hit so
hard by this disaster, and it was natural for us to offer prompt
assistance. Our sympathy goes to all residents of the Gulf region who have
lost family members or been made homeless and need help."
Bayer HealthCare Diabetes Care Division
Bayer HealthCare Diabetes Care Division is one of the largest self test
diagnostic businesses in the world, supporting customers in 100 countries.
Since the introduction of Clinitest® reagent tablets in 1941 - Bayer has
led the way in diabetes care product innovation. The company changed the
face of diabetes care in 1969 when it introduced the first portable blood
glucose meter and strips. Bayer HealthCare further innovated diabetes self
management by being the first company to introduce a suite of blood glucose
monitors that do not require coding. The Ascensia® BREEZE®, Ascensia®
CONTOUR®, and Ascensia® DEX®2 systems offer people with diabetes
unparalleled choice in blood glucose monitoring meters.
Bayer HealthCare Diabetes Care Division sponsors the annual Ascensia Dream
Fund® contest (www.AscensiaDreamFund.com) - a
national contest for people with diabetes 18 and older to win up to
$100,000 to achieve their dream - whatever it may be.
Bayer HealthCare Diabetes Care Division's global headquarters in the
United States operates as part of Bayer HealthCare LLC, a member of the
worldwide Bayer HealthCare group.
Bayer Corporation, headquartered in Pittsburgh, is a subsidiary of Bayer
AG, an international health care, nutrition and innovative materials
company based in Leverkusen, Germany. In North America, Bayer employs
about 16,000 and had net sales in 2004 of 8.3 billion euros. Bayer's
three operating companies -- Bayer HealthCare LLC, Bayer CropScience LP
and Bayer MaterialScience LLC -- improve people's lives through a broad
range of essential products that help diagnose and treat diseases, protect
crops and advance automobile safety and durability.
# # #
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known
and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in our public reports filed with the
Frankfurt Stock Exchange and with the U.S. Securities and Exchange
Commission (including our Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to conform them
to future events or developments.
|
|